AFFiRiS AG
Karl-Farkas-Gasse 22
Vienna
1030
Tel: 43-1-7981575-300
Fax: 43-1-7981575-311
Website: http://www.affiris.com/
Email: office@affiris.com
26 articles about AFFiRiS AG
-
AC Immune acquires AFFiRiS’ Specific Active Immunotherapy (SAIT) anti-alpha-synuclein programs targeting neurodegenerative diseases
7/27/2021
AFFiRiS AG, a clinical-stage biotechnology company that has been engaged in the development of novel disease-modifying Specific Active Immunotherapies (SAITs), today announced that AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, is acquiring AFFiRiS’ anti-alpha-synuclein programs targeting neurodegenerative diseases caused by misfolded forms of human self-proteins.
-
AFFiRiS: Positive phase 1 results with immunotherapies targeting PCSK9 to treat hypercholesterolemia published by the European Journal of Clinical Pharmacology
5/27/2021
Repeated immunization with AFFITOPE® peptide active immunotherapy candidates AT04A and AT06A is safe, well-tolerated and induces a strong and long-lasting PCSK9-specific immune response
-
Positive preclinical in vivo results with AFFiRiS’ antibody mAB C6-17 to treat Huntington’s disease to be presented at the 16th Annual Huntington's Disease Therapeutics Conference
4/27/2021
Monoclonal antibody C6-17 designed to target mutant huntingtin protein (mtHTT) and to reduce spread of Huntington’s disease pathology
-
AFFiRiS granted new patent in China for treating Parkinson's disease
3/3/2020
Patent adds to company’s robust portfolio covering clinical stage lead development candidate PD01
-
AFFiRiS Announces FDA Response to its pre-IND Submission for Phase 2 Trial with AFFITOPE(R) PD01 in Early Parkinson's Disease Patients Study start in the US and Europe confirmed for H2 2020
1/27/2020
AFFiRiS AG, a clinical-stage biopharmaceutical company developing novel disease-modifying specific active immunotherapies (SAITs) for patients with neurodegenerative diseases, today announced it had received feedback to its pre-Investigational New Drug ("IND") submission to the U.S. Food and Drug Administration ("FDA") regarding the planned Phase 2 clinical trial with AFFITOPE(R) PD01,
-
AFFiRiS AG Announces Top Line Results Of First-In-Human Clinical Study Using AFFITOPE PD03A, Confirming Immunogenicity And Safety Profile In Parkinson's Disease Patients
6/7/2017
-
Boost Vaccination Data Encourage Continued Development of AFFiRiS AG Therapeutic Parkinson's Disease Vaccine Against Alpha-Synuclein
9/7/2016
-
AFFiRiS AG Successfully Raises €10 Million Equity Financing
6/23/2016
-
Vaccine Specialist AFFiRiS AG Successfully Completes Financing Round
6/16/2015
-
AFFiRiS AG Announces Management Changes
2/5/2015
-
New Board Member Joins AFFiRiS AG
9/9/2014
-
AFFiRiS AG Release: First Clinical Data Of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development
7/31/2014
-
AFFiRiS AG Presents Phase I Data On A First-Of-Its-Kind Treatment With Support From The Michael J. Fox Foundation
7/31/2014
-
AFFiRiS AG Presents Early Clinical Data On A First-Of-Its-Kind Parkinson's Disease Vaccine
7/29/2014
-
Media Advisory: AFFiRiS AG Presents Early Clinical Data On A First-Of-Its-Kind Parkinson's Disease Vaccine
7/24/2014
-
AFFiRiS AG Presents Early Clinical Data On A First-Of-Its-Kind Parkinson's Disease Vaccine
7/24/2014
-
Breakthrough: AFFiRiS AG Claims A First In Alzheimer's Disease Therapy
6/6/2014
-
AFFiRiS AG Release: Parkinson's Vaccine - Worldwide First Clinical Study in Vienna
6/5/2012
-
AFFiRiS AG Inverts into Human Capital - Chief Business Officer Recruited
12/5/2011
-
Capital Increase: AFFiRiS AG Brings Santo VC and MIG 11 on Board
11/8/2011